Allakos (ALLK) said Thursday results of a phase 1 trial showed that a subcutaneously administered AK006, its investigational monoclonal antibody that selectively inhibits mast cells, was "well-tolerated with a favorable safety profile."
The company reported data from single dose subcutaneous AK006 up to 720 milligrams, with skin biopsies taken from treated healthy volunteers showing high levels of receptor occupancy, confirming that AK006 reached skin tissue mast cells. The results were consistent with the trial of intravenously-administered AK006, it said.
The results showed there were no serious adverse events in subjects, no treatment emergent adverse events leading to discontinuation of AK006, and no dose limiting toxicities, Allakos said.
The company expects topline phase 1 results of intravenous AK006 in patients with chronic spontaneous urticaria in early Q1 next year.
Shares of the company were advancing over 7% in extended trading.
Price: 0.7076, Change: +0.05, Percent Change: +7.37
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。